UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 16, 2020
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) | ||||||||||||
(Address of principal executive offices, including zip code)
Registrant’s telephone number, including area code: 781 -848-7100
(Former name or former address, if changed since last report.)
| Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
| Securities registered pursuant to Section 12(b) of the Act: | ||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
| Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||
Emerging Growth Company | ||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ | ||
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d)
On April 16, 2020, the Board of Directors of Haemonetics Corporation (the “Company”) elected Michael J. Coyle as a director of the Company, effective immediately. Mr. Coyle serves as the Executive Vice President and Group President, Cardiac and Vascular Group for Medtronic, where he oversees four of the company’s business divisions, providing strategic direction and ensuring the alignment of integrated growth plans and cross-functional synergies.
Mr. Coyle, who will stand for election by shareholders at the Company’s 2020 Annual Meeting of Shareholders, has also been appointed to serve on the Audit Committee and Governance and Compliance Committee of the Board of Directors beginning at each committee's next regularly scheduled quarterly meeting. As a non-employee director of the Company, Mr. Coyle will receive compensation as described in the “Directors' Compensation” section of the Company's 2019 proxy statement, with his prorated annual equity award based on a $180,000 full-year award value. Mr. Coyle will also enter into the Company's standard form of indemnification agreement, the form of which was previously filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2018.
A copy of the Company’s press release announcing the election of Mr. Coyle is filed as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit Number | Description | |||||||
| Press release dated April 17, 2020. | ||||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HAEMONETICS CORPORATION | ||||||||||||||
| April 17, 2020 | By: | /s/ Christopher A. Simon | ||||||||||||
| Name: | Christopher A. Simon | |||||||||||||
| Title: | President and Chief Executive Officer | |||||||||||||
For Immediate Release
Investor Contact: Olga Guyette, Director-Investor Relations (781) 356-9763 olga.guyette@haemonetics.com | Media Contact: Carla Burigatto, Vice President-Communications (781) 348-7263 carla.burigatto@haemonetics.com | |||||||
Michael Coyle Joins Haemonetics Board of Directors
BOSTON, MA, April 17, 2020 - Haemonetics Corporation (NYSE: HAE), a global medical technology company focused on delivering innovative hematology solutions to drive better patient outcomes, announced the election of Michael Coyle to its Board of Directors.
Coyle serves as the Executive Vice President and Group President, Cardiac and Vascular Group for Medtronic where he oversees four of the company’s business divisions, providing strategic direction and ensuring the alignment of integrated growth plans and cross-functional synergies.
Coyle previously served on the boards of VNUS Medical Technologies, Inc. and Volcano Corporation, medical device companies responsible for making catheter-based products.
"Mike brings years of valuable expertise in the medical device space, including building global businesses and bringing technologies to important medical markets, that will be an asset as Haemonetics pursues transformational growth and advances its Innovation Agenda," said Richard J. Meelia, Chairman of Haemonetics' Board of Directors.
Before joining Medtronic, Coyle provided leadership consulting services to private equity, venture capital and medical device technology firms. From 2001 to 2007, he served as a divisional president at St. Jude Medical where he led the company’s global pacemaker, implantable cardioverter defibrillator, and cardiac resynchronization businesses. Coyle also led the company’s Daig Catheter division in an earlier president role. Additionally, he held numerous leadership positions at Eli Lilly & Company.
Coyle earned a bachelor’s degree from Case Western Reserve University and a master’s degree in business administration from the Wharton School of Business, University of Pennsylvania and is currently an advisor on the Case Western Reserve University School of Engineering BME Think Tank. He holds six U.S. patents related to Cardiovascular Medical Device Products and Technologies.
About Haemonetics
Haemonetics (NYSE: HAE) is a global healthcare company dedicated to providing a suite of innovative hematology products and solutions for customers, to help them improve patient care and reduce the cost of healthcare. Our technology addresses important medical markets: blood and plasma component collection, the surgical suite and hospital transfusion services. To learn more about Haemonetics, visit www.haemonetics.com.